Search results
Results from the WOW.Com Content Network
This article lists veterinary pharmaceutical drugs alphabetically by name. Many veterinary drugs have more than one name and, therefore, the same drug may be listed more than once. Abbreviations are used in the list as follows: INN = International Nonproprietary Name; BAN = British Approved Name; USAN = United States Adopted Name
ATC code C10 Lipid modifying agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Pravastatin was patented in 1980 and approved for medical use in 1989. [6] It is on the World Health Organization's List of Essential Medicines. [7] It is available as a generic medication. [5] In 2022, it was the 37th most commonly prescribed medication in the United States, with more than 16 million prescriptions. [8] [9]
Some patients request to be switched to a different narcotic due to stigma associated with a particular drug (e.g. a patient refusing methadone due to its association with opioid addiction treatment). [4] Equianalgesic charts are also used when calculating an equivalent dosage of the same drug, but with a different route of administration.
Atorvastatin, pravastatin or fluvastatin: Negative interactions are more likely with other choices. [61] Persons taking gemfibrozil, a non-statin lipid-lowering drug Atorvastatin Combining gemfibrozil and a statin increases risk of rhabdomyolysis and subsequently kidney failure [62] [63] Persons taking the anticoagulant warfarin: Any statin
The two-year ENHANCE Study [7] failed to provide evidence that ezetimibe/simvastatin was better than simvastatin (a generic medication) in terms of achieving a lower change from baseline in carotid intima-media thickness despite lower LDL levels in a population of patients with heterozygous familial hypercholesterolemia (a form of high ...
The effects of rosuvastatin on low-density lipoprotein (LDL) cholesterol are dose-related. Higher doses were more efficacious in improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin.
In five RCTs a mean atorvastatin dose of 26 mg/day reduced LDL cholesterol by 44.0% and reduced myocardial infarction, relative risk, 0.67 (95% CI 0.58 to 0.77) as compared to placebo. In four RCTs a mean rosuvastatin dose of 16 mg/day reduced LDL cholesterol by 48.8% and reduced myocardial infarction, relative risk, 0.82 (95% CI 0.73 to 0.93 ...